ANUH PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 227.6 INR | -0.22% |
|
-2.40% | +55.29% |
| Sales 2022 | 486.65Cr 5.83Cr | Sales 2023 | 527.49Cr 6.32Cr | Capitalization | 398.99Cr 4.78Cr |
|---|---|---|---|---|---|
| Net income 2022 | 31Cr 36.69L | Net income 2023 | 36Cr 43.4L | EV / Sales 2022 | 0.84 x |
| Net cash position 2022 | 21Cr 25.23L | Net cash position 2023 | 52Cr 62.55L | EV / Sales 2023 | 0.66 x |
| P/E ratio 2022 |
14.1
x | P/E ratio 2023 |
11
x | Employees | 159 |
| Yield 2022 |
2.04% | Yield 2023 |
2.51% | Free-Float | 30.08% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.22% | ||
| 1 week | -2.40% | ||
| 1 month | -7.95% | ||
| 3 months | +3.15% | ||
| 6 months | +45.51% | ||
| Current year | +55.29% |
1 week
222.00
236.00
1 month
221.00258.00
Current year
155.00265.00
1 year
89.00265.00
3 years
77.00265.00
5 years
48.70265.00
10 years
33.33265.00
| Managers | Title | Age | Since |
|---|---|---|---|
Vivek Bipin Shah
CEO | Chief Executive Officer | 38 | 01/17/01 |
| Chief Executive Officer | 43 | - | |
| Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 67 | 24/08/24 | |
| Director/Board Member | - | 07/49/07 | |
| Director/Board Member | 78 | 29/80/29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 227.6 | -0.22% | 51,316 |
| 30/24/30 | 228.2 | -1.19% | 48,625 |
| 29/24/29 | 230.9 | -0.47% | 31,810 |
| 28/24/28 | 232 | +1.73% | 55,841 |
| 27/24/27 | 228 | -2.23% | 69,205 |
Delayed Quote Bombay S.E., May 31, 2024 at 03:30 pm IST
More quotes
Anuh Pharma Limited is an India-based bulk drug manufacturing company. The Company is engaged in the business of manufacturing active pharmaceutical ingredients (API). The Company manufactures Macrolides, Anti-TB, Anti-Bacterials, Anti-Malarial, Anti-Hypertension, Expectorant and Corticosteroids products. Its Macrolides products include Erythromycin, Erythromycin Ethyl Succinate, Erythromycin Stearate, Erythromycin Estolate, Erythromycin Propionate, Erythromycin Phosphate, Erythromycin 11,12 Carbonate and Azithromycin. Its Anti-TB products include Pyrazinamide and Isoniazid. Its Anti-Malarial products include Sulfadoxine and Pyrimethamine. Anti-Bacterials products include Chloramphenicol and Chloramphenicol Palmitate. Anti-Hypertension products include Losartan Potassium, Telmisartan and Atorvastatin Calcium. Its Expectorant product includes Ambroxol Hydrochloride. Its Quinolones product includes Moxifloxacin Hydrochloride.
Sector
Pharmaceuticals
Calendar
09/08/2024
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +55.29% | 14Cr | |
| +15.91% | 4.2TCr | |
| +23.31% | 2.23TCr | |
| +18.48% | 1.52TCr | |
| +16.12% | 1.4TCr | |
| +45.12% | 1.21TCr | |
| -9.32% | 679.6Cr | |
| -0.05% | 678.76Cr | |
| -8.87% | 572.55Cr | |
| +14.18% | 549.33Cr |
- Stock Market
- Equities
- 506260 Stock
